[go: up one dir, main page]

MX2021008208A - Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. - Google Patents

Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.

Info

Publication number
MX2021008208A
MX2021008208A MX2021008208A MX2021008208A MX2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A MX 2021008208 A MX2021008208 A MX 2021008208A
Authority
MX
Mexico
Prior art keywords
tesofensine
prader
body weight
reduction
willi
Prior art date
Application number
MX2021008208A
Other languages
English (en)
Inventor
Jørgen Drejer
Thomas Amos Jacobsen
Thomas Feldthus
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3029052A external-priority patent/CA3029052A1/en
Priority claimed from CA3058933A external-priority patent/CA3058933A1/en
Application filed by Saniona As filed Critical Saniona As
Publication of MX2021008208A publication Critical patent/MX2021008208A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con un método de reducción del peso corporal o hiperfagia en pacientes con síndrome de Prader-Willi que comprende administrar el compuesto activo Tesofensina o una sal farmacéuticamente aceptable del mismo, preferiblemente por la administración de una formulación de liberación controlada que comprende los compuestos activos de tesofensina y un bloqueador delta. La invención se relaciona además con composiciones farmacéuticas que comprenden más de 0.150 mg de Tesofensina o una sal farmacéuticamente aceptable de la misma y no más de 25 mg de Metoprolol.
MX2021008208A 2019-01-07 2020-01-07 Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi. MX2021008208A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA3029052A CA3029052A1 (en) 2019-01-07 2019-01-07 Tesofensine for reduction of body weight in prader-willi patients
CA3058933A CA3058933A1 (en) 2019-10-16 2019-10-16 Tesofensine for reduction of body weight in prader-willi patients
PCT/EP2020/050153 WO2020144146A1 (en) 2019-01-07 2020-01-07 Tesofensine for reduction of body weight in prader-willi patients

Publications (1)

Publication Number Publication Date
MX2021008208A true MX2021008208A (es) 2021-11-17

Family

ID=69165342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008208A MX2021008208A (es) 2019-01-07 2020-01-07 Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.

Country Status (4)

Country Link
US (1) US20220160658A1 (es)
BR (1) BR112021013463A2 (es)
MX (1) MX2021008208A (es)
WO (1) WO2020144146A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151210A3 (en) * 2020-01-10 2023-06-14 Harmony Biosciences, LLC Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
WO2021214233A1 (en) * 2020-04-22 2021-10-28 Saniona A/S Treatment of hypothalamic obesity
CA3244552A1 (en) * 2022-02-28 2023-08-31 Noema Pharma Ag TRIPLE ABSORBENT INHIBITOR FOR THE TREATMENT OF ATYPICAL DEPRESSION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3238414B2 (ja) 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2004069234A1 (en) 2003-02-05 2004-08-19 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
WO2007110753A2 (en) 2006-03-28 2007-10-04 Wockhardt Ltd Extended release dosage forms of metoprolol
EP2063876A1 (en) 2006-07-28 2009-06-03 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
US9446032B2 (en) 2011-08-26 2016-09-20 Wockhardt Limited Methods for treating cardiovascular disorders
EP2841061A1 (en) 2011-12-09 2015-03-04 Wockhardt Limited Methods for treating cardiovascular disorder
JP6203760B2 (ja) 2012-02-16 2017-09-27 サニオナ・エー／エス 併用療法のための医薬組成物
WO2015004617A1 (en) 2013-07-09 2015-01-15 Ranbaxy Laboratories Limited Extended-release pharmaceutical compositions of metoprolol
LT3265126T (lt) * 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija
EP3402473A1 (en) * 2016-01-15 2018-11-21 Saniona A/S Tesofensine and metoprolol for treatment of hypertension

Also Published As

Publication number Publication date
BR112021013463A2 (pt) 2021-09-14
WO2020144146A1 (en) 2020-07-16
US20220160658A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2024007720A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
IL178745A (en) Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
US20150005262A1 (en) Hypoxia activated prodrugs and mtor inhibitors for treating cancer
MX2021008208A (es) Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
JP2012502047A5 (es)
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
JP2018522920A5 (es)
HK1042303A1 (zh) 新的化合物
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
MX2011002177A (es) Metodo para combatir efectos adversos que surgen del tratamiento antipsicotico.
RU2016137926A (ru) Композиции грапипранта и способы их применения
JP2019509309A5 (es)
EP2599487B1 (en) Therapeutic agent or prophylactic agent for neuropathic pain
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
JP6928611B2 (ja) 組合せ
KR100844256B1 (ko) 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
AU2002251763B2 (en) Method for treating cancer
KR20250159241A (ko) 종양학 병용 요법 및 사용 방법
HUP0103149A2 (hu) Gyógyszerkészítmény Alzheimer-kór kezelésére
MX2024002494A (es) Composiciones para prevenir o tratar la enfermedad de charcot-marie-tooth (cmt).